Human Metabolome Technologies, Inc. (6090)

Market cap
¥3.7B
P/E ratio
17.3x
Provides high-sensitivity analysis of metabolic compounds to pharmaceutical companies, research institutions, and manufacturers to support drug development and product testing.
Period EndDepreciation & amortization (Million JPY)YoY (%)
Jun 30, 2025104+20.27%
Jun 30, 202486+7.38%
Jun 30, 202380+23.87%
Jun 30, 202265+16.21%
Jun 30, 202156+16.43%
Jun 30, 202048-40.77%
Jun 30, 201981+31.73%
Mar 31, 201861+15.45%
Mar 31, 201753-13.37%
Mar 31, 201661-13.61%
Mar 31, 201571
AI Chat